Publications

5808 Results

Bacillus Calmette-Gue'rin manufacturing and SWOG S1602 Intergroup clinical trial [editorial]

Authors
JJ Meeks;SP Lerner;RS Svatek
Journal / Conference
Journal of Urology Mar;197(3 Pt 1):538-540; Epub 2016 Dec 16
Year
2017
Research Committee(s)
Genitourinary
PMID
PMID27992750
PMC
PMC n/a - editorial
Study Number(s)
S1602

Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313)

Authors
P Sharma;W Barlow;A Godwin;L Knight;SM Walker;RD Kennedy;S Badve;Y Gokmen-Polar;H Pathad;S Isakova;H Linden;D Tripathy;G Hortobagyi;D Hayes
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 529); American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Breast
Study Number(s)
SWOG-9313

SWOG S0221 Updated: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer

Authors
GT Budd;W Barlow;HCF Moore;T Hobday;JA Stewart;C Isaacs;M Salim;JK Cho;K Rinn;KS Albain;HK Chew;GV Burton;TD Moore;G Srkalovic;BA McGregor;LE Flaherty;RB Livingston;JR Gralow;G Hortobagyi
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 521); American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Breast
Study Number(s)
S0221

Effects of neoadjuvant chemotherapy (NAC) on tumor infiltrating lymphocytes (TIL) and PD-L1 expression in the SWOG S0800 clinical trial

Authors
V Pelekanou;W Barlow;M-C vonWahlde;B Wasserman;YC Lo;DF Hayes;G Hortobagyi;J Gralow;D Tripathy;RB Livingston;ZA Nahleh;DL Rimm
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 519); American Society of Clinical Oncology (ASCO) Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Breast
Study Number(s)
S0800

Impact of value of information analyses on SWOG’s clinical trial capsule scoring

Authors
JJ Carlson;D Kim;G Guzauskas;C Bennette;DL Hershman;L Baker;N Hendrix;A Basu;DL Veenstra;S Ramsey
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr e18311); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017Chicago, IL), publish only
Year
2017
Research Committee(s)
Cancer Care Delivery

National coverage analyses for NCI clinical trials: A pilot project to reduce participation barriers

Authors
A Denicoff;G Mishkin;M Good;L Patrichuk;L Ragard;KR Hurtado;K Willenberg;C Szczepanek;C Dawson;M Alexander-Young;D Stranberg;J Kardell;S McCartney;MB Sullivan;M Kelly;MJ Montello;W McCaskill-Stevens;J Abrams;M Mooney
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 6542); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Cancer Care Delivery

The scientific impact and value of large, NCI-sponsored randomized phase III cancer prevention trials

Authors
J Unger;W Barlow;C Tangen;S Ramsey;IM Thompson;EA Klein;M Leblanc;C Blanke;P Goodman;L Minasian;D Hershman
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 1541); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster session
Year
2017
Research Committee(s)
Cancer Control, Prevention, Screening, and and Surveillance
Study Number(s)
S0000, SWOG-9217

The impact of positive SWOG treatment trials on population survival

Authors
J Unger;M LeBlanc;C Blanke
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 6513); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Breast, Cancer Care Delivery, Gastrointestinal, Genitourinary, Gynecologic, Head and Neck, Leukemia, Lung, Lymphoma, Multiple sites, and Myeloma
Study Number(s)
S0226, S0777, SWOG-7436, SWOG-7704/05, SWOG-7817, SWOG-8494 (INT-0036), SWOG-8501 (INT-0051), SWOG-8591(NCI Intergroup #0035), SWOG-8624, SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891), SWOG-8736 (INT-0093), SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12), SWOG-8814, SWOG-8892 (INT-0099) (EST-2388) (RTOG-8817), SWOG-8897, SWOG-8949, SWOG-9008 (INT-0116) (RTOG-9018) (NCCTG-90-41-51) (ECOG-6290) (CALGB-9195), SWOG-9126, SWOG-9210, SWOG-9308, S9916

A randomized phase II pilot study prospectively evaluating treatment for patients based on ERCC1 (Excision Repair Cross-Complementing 1) for advanced/ metastatic esophageal, gastric or gastroesophageal junction (GEJ) cancer: SWOG S1201

Authors
S Iqbal;S McDonough;H Lenz;D Ilson;B Burtness;CS Nangia;A Barzi;CJ Schneider;J Liu;E Dotan;K Guthrie;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4009); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussion
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1201

SWOG S1310: Randomized phase II trial of single agent MEK inhibitor trametinib vs. 5-fluorouracil or capecitabine in refractory advanced biliary cancer

Authors
R Kim;S McDonough;A El-Khoueiry;T Bekaii-Saab;SM Stein;V Sahai;GP Keogh;EJ Kim;AD Baron;AB Siegel;A Barzi;K Guthrie;M Javle;H Hochster
Journal / Conference
J Clin Oncol 35, 2017 (suppl; abstr 4016); American Society of Clinical Oncology Annual Meeting (June 2-6, 2017, Chicago, IL), poster discussioin
Year
2017
Research Committee(s)
Gastrointestinal
Study Number(s)
S1310